A Comparative Analysis of Efficacy of Apatinib Combined with Transarterial Chemoembolization and Transarterial Chemoembolization Alone in the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

Table 2

Adverse events before PSM analysis.

Adverse events	Any grades	value	≥3 grade	value
	TACE + apatinib (n = 53)	TACE alone (n = 56)		TACE + apatinib (n = 53)	TACE alone (n = 56)
Hand-foot skin reactions	44 (83.0%)	0	≤0.001	4 (7.5%)	0	0.053
Hypertension	24 (45.3%)	5 (8.9%)	≤0.001	1 (1.9%)	0	0.486
Diarrhea	10 (18.9%)	8 (14.3%)	0.520	0	0
Fatigue	6 (11.3%)	7 (12.5%)	0.849	0	0
Oral ulcer	3 (5.7%)	0	0.223	0	0
Voice change	3 (5.7%)	1 (1.8%)	0.572	1 (1.9%)	0	0.486
Proteinuria	10 (18.9%)	2 (3.6%)	0.025	1 (1.9%)	0	0.486
Gastrointestinal hemorrhage	4 (7.5%)	0	0.053	0

TACE, transarterial chemoembolization; PSM, propensity score matching.